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Abstract
Background
Erectile dysfunction (ED) is common among men on opioid replacement therapy (ORT), but
most previous studies exploring its prevalence and determinants yielded contrasting find-
ings. Moreover, the impact of ED on patients’ quality of life (QoL) has been seldom
explored.
Objective
To explore the prevalence and determinants of ED in men on ORT, and the impact on QoL.
Methods
In a multicentre cross-sectional study, we recruited 797 consecutive male patients on meth-
adone and buprenorphine treatment, collected data on demographic, clinical, and psycho-
pathological factors, and explored their role as predictors of ED and QoL through univariate
and multivariate analysis. ED severity was assessed with a self-assessment questionnaire.
Results
Nearly half of patients in our sample were sexually inactive or reported some degree of ED.
Some demographic, clinical and psychopathological variables significantly differed accord-
ing to the presence or absence of ED. Multivariate regression analysis indicated that age,
employment, smoke, psychoactive drugs, opioid maintenance dosage, and severity of
psychopathological factors significantly influenced the risk and severity of ED. QoL was
worse in patients with ED and significantly correlated with ED severity. Age, education,
employment, opioid maintenance dosage, ED score, and severity of psychopathology sig-
nificantly influenced QoL in the multivariate analysis.
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Conclusions
ED complaints can be explored in male opioid users on ORT through a simple and quick
self-assessment tool. ED may have important effects on emotional and social well-being,
and may affect outcome.
Introduction
Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection satisfac-
tory for the completion of sexual activity [1]. ED is a prevalent health condition, which is esti-
mated to affect 17.7–18.4% men aged 20 years in the USA [2,3] and 32.2% in Europe [4],
may be episodic or chronic, and can be associated with other sexual dysfunctions including
reduced sexual desire and premature ejaculation [5]. Common risk factors for ED encompass
age, obesity, diabetes, hyperlipidemia, lower urinary tract symptoms, hypertension, low physi-
cal activity, smoke [2,4], psychiatric conditions and psychological factors [5].
Opioids may increase sexual desire in the short term [6], but their long term use is known
to negatively impact on sexual function and to lead to erectile dysfunction (ED) [7,8]. Various
studies explored ED in men on opioid replacement therapy (ORT) and reported a 21–52%
prevalence [7,9–11], with a peak of approximately 80% in a longitudinal study on a small
group of patients in China [12]. Most studies were on small samples of men on ORT, but a
meta-analysis suggested that factors associated with sexual dysfunction include age, familial
status, medical comorbidity, psychiatric illness, testosterone levels, opioid dosage, duration of
treatment, and other current substance use disorders [13].
The majority of studies on ED were conducted on men under methadone maintenance
treatment, and a meta-analysis indicated a 52% pooled prevalence for sexual dysfunction
among methadone users [11]. Buprenorphine was introduced more recently as an alternative
ORT [8]. European data indicate that methadone is prescribed in approximately 63% of
patients, while buprenorphine is prescribed in 37% of them, although these figures differ
greatly from country to country [14]. There is agreement that substitution treatment, either
methadone or buprenorphine, may improve ED in opioid users [6,15].
Pharmacodynamics of methadone and buprenorphine differ, in that the former is a μ-opi-
oid receptor agonist, while the latter is a mixed agonist-antagonist opioid that acts on the μ-
opioid receptor with low intrinsic activity and high affinity, and on the κ-opioid receptor with
no intrinsic activity but high affinity [7,8].
Human and animal data indicate that opioids may act at different sites in the hypotha-
lamic–pituitary axis, and lead to opioid associated androgen deficiency (OPIAD), an endo-
crine dysfunction that includes increase of prolactin and decrease of follicle stimulating
hormone, luteinizing hormone, testosterone, estradiol, and oxytocin [16,17]. OPIAD results in
hypogonadism, and is reported to occur after a few weeks of opioid intake and when exceeding
a daily oral morphine milligram equivalent dosage (OMMED) of 100 mg [17]. Animal data
suggest lower risk of OPIAD with buprenorphine than methadone probably through the offset
of hypothalamic–pituitary axis inhibition related to κ-opioid receptor antagonist activity [18].
Data from humans are discordant, in that some studies reported more frequent sexual and ED
to methadone, while other ones found no significant differences between the two maintenance
treatments [7–9,19,20].
Sexual functioning is an important determinant of quality of life (QoL), but the effect of ED
on QoL has been seldom explored in men under ORT [8,21,22].
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The aims of the present cross-sectional multicentre study are to explore the prevalence and
severity of ED in patients under methadone or buprenorphine maintenance treatment, the fac-
tors related to ED, and the impact of ED on patient’s QoL. To this aim, we recruited a large
sample of patients, collected data on a number of demographic, clinical, and psychopathologi-
cal factors, and explored their role as predictors of ED and QOL through univariate and multi-
variate analysis.
Materials and methods
Patients were recruited from November 1st, 2014 to January 31st, 2015 in twenty-two National
Health Service Drug Addiction Units that belong to the Gruppo InterSERT di Collaborazione
Scientifica (GICS), a scientific collaborative network dealing with drug-related problems and
located in Italy. The inclusion criteria were: a) male sex, b) age 18 years or older, c) history of
opioid use, d) having been on oral methadone or oral buprenorphine treatment for at least 6
months, e) absence of any relevant comorbidity that might have influenced erection and/or
QoL, including diabetes mellitus, peripheral vascular disease, neurological diseases that may
be associated with ED (stroke, Parkinson’s disease, multiple sclerosis, spinal cord injury),
severe obesity (i.e., body mass index > 35), drugs that might interfere with sexual function
including hormonal treatment for prostate cancer or benign prostatic hypertrophy, urological
conditions or previous surgical procedures that might cause ED, cancer, severe heart, lung,
liver or kidney disease. Written informed consent was obtained prior to inclusion in the study,
which was conducted in accordance with the declaration of Helsinki and approved by the Eth-
ics Committee of the Verona University Hospital. No benefit was provided for participation in
the study that was voluntary and confidential.
Demographic (age; education: grade school, high school, university; employment: unem-
ployed, employed; marital status: single or divorced, engaged or married; parenthood: no, yes),
and clinical variables (type of opioid: methadone, buprenorphine; daily OMMED: mg; smoke:
yes, no; cigarettes: cigarettes/day; psychoactive drugs: yes/no; type of psychoactive drug: ben-
zodiazepine, antidepressants, antipsychotics, more than one) were derived from clinical rec-
ords. OMMED was calculated using standard dosage conversion calculations, i.e. a conversion
factor of 4.7 for methadone and of 37.5 for oral buprenorphine [23].
Psychopathological symptoms were measured with the Symptom Check List-90-R (SCL-
90-R), a widely-used 90-item scale that includes a number of different subscales exploring the
severity of respondents’ symptoms over the previous seven days [24]. Each SCL-90-R item is
rated on a 5-point Likert scale ranging from ‘not at all’ (0) to ‘extremely’ (4). We derived nine
subscales, i.e., somatization (SOM), obsessive-compulsive (OC), interpersonal sensitivity (IS),
depression (DEP), anxiety (ANX), hostility (HOS), phobic anxiety (PHO), paranoid ideation
(PAR), and psychoticism (PSY), and the global severity index (GSI) from the Italian Version of
the SCL-90-R [25]. The GSI, which was obtained by adding the scores of all 90 items and divid-
ing by 90, is considered the single best indicator of the current level or depth of an individual’s
disorder, in that it combines information concerning the number of symptoms reported with
the intensity of perceived distress [25].
Erectile function was explored with the abridged five-item version of the International
Index of Erectile Function (IIEF-5), a self-administered questionnaire that explores quality of
erectile function and sexual intercourse confidence and satisfaction [26]. Each IIEF-5 item is
rated on a 5-point Likert scale, ranging from 1 to 5, with higher scores indicating better erectile
function and satisfaction. The severity of ED (range: 5–25) was graded as none (IIEF-5 score:
22–25), mild (17–21), mild to moderate (12–16), moderate (8–11), and severe (5–7), and the
absence of sexual intercourses was also recorded [26].
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QoL was scored with the 12-Items General Health Questionnaire (GHQ-12), one of the
most widely used screening tool, which measures changes in psychological health and is com-
posed of 12 questions on mood states over the previous two weeks: lost sleep, feelings of being
under strain, could not concentrate, felt unable to play a useful role, could not face problems,
could not make decisions, could not overcome difficulties, felt unhappy, did not enjoy day-to-
day activities, felt depressed, lost confidence, and felt worthless [27]. GHQ-12 items were
scored on a 4-point scale, ranging from 0 to 3, with higher values indicating more severe psy-
chological distress, and the overall score (range: 0–36) was calculated [27].
Statistical analysis
All tests were carried with the IBM SPSS version 20.0 statistical package. The normality of vari-
able distribution was analyzed with the Skewness-Kurtosis test. The Pearson’s χ2 test and Bon-
ferroni’s corrected post-hoc with the non-parametric Mann-Whitney U test were applied to
categorical variables. For continuous variables, the one-way ANOVA and post-hoc with Bon-
ferroni’s correction were used in case of normal distribution, while the Kruskal Wallis H test
and Bonferroni’s corrected Mann-Whitney U tests were applied if the distribution was not
normal. The homogeneity of variances was analyzed with the Levene’s test, and the data were
logarithmically transformed before submitting them to ANOVA if the variances were inhomo-
geneous. Correlations were explored with the Spearman’s ρ correlation coefficient. Multivari-
ate analysis was used to explore the influence of the demographic and clinical covariates on
ED and QoL measures. Linear regression model analysis was applied for IIEF-5 and GHQ-12
scores (continuous dependent variables). The risk of having ED was also explored with logistic
regression model analysis (binary dependent variable: any ED, no ED), and the results were
expressed as odd ratios and 95% confidence intervals (CI). The goodness of fit of the logistic
regression model was assessed using the Hosmer and Lemeshow test [28]. P< 0.05 (two-
tailed) was taken as the significance threshold for all the tests.
Results
We recruited 1000 consecutive male patients. Demographic and clinical characteristics of
those (N = 797, 79.7%), who answered the IIEF-5 questionnaire, are reported in Tables 1 and
2, respectively and the full dataset is attached as supporting information (S1 Dataset). In our
cohort, 598 patients (75.0%) were taking oral methadone (average daily dosage: 58.0 ± 47.3
mg, median: 50, range: 2–350), and 199 patients (25.0%) were on oral buprenorphine (average
daily dosage: 8.3 ± 6.7 mg, median: 6, range: 0.5–40).
Table 1. Demographic characteristics of the patients.
Variable
Age (y) mean: 38.6 ± 9.9, median: 39, range: 18–66
Education‡ 493 (61.9%), 283 (35.5%), 21 (2.6%)
Employment‡ 366 (45.9%), 431 (54.1%)
Marital status§ 669 (83.9%), 128 (16.1%)
Parenthood¶ 681 (85.4%), 116 (14.6%)
†Education: grade school, high school, university (%).
‡Employment: unemployed, employed (%).
§Marital status: single/divorced, engaged/married (%).
¶Parenthood: no, yes (%).
https://doi.org/10.1371/journal.pone.0188994.t001
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According to IIEF-5 score, 96 patients (12.0%) were sexually inactive, 22 (2.8%) had severe
ED, 49 (6.1%) had moderate ED, 86 (10.8%) had mild to moderate ED, 136 (17.1%) had mild
ED, and 408 (51.2%) reported no ED. In sexually active patients, average IIEF-5 score was
20.4 ± 5.4 (median: 23, range: 5–25). Only 19 patients (2.4% of the whole sample, 6.4% of sexu-
ally active patients with any ED) were under treatment for ED that was prescribed by the Drug
Addiction Unit physicians in 4 of them. None of them was treated with androgen replacement
therapy.
Patients were grouped into sexually inactive ones (N = 96), those with any ED (i.e., mild to
severe, IIEF-5 score < 22, N = 293), and those with no ED (i.e., IIEF-5 score 22, N = 408).
Age significantly differed according to the group, in that it was larger in sexually inactive
patients (42.9 ± 11.3 years) than those with any ED (39.4 ± 9.5) and those with no ED (37.2 ±
9.5; p< 0.001), and all post-hoc comparisons were significant between the three groups
(Table 3).
Employment status was significantly different between groups (p = 0.034), and post-hoc
showed a significantly larger number of employed patients (58.1%) in the no ED group than
the sexually inactive one (44.8%; Table 3). Smoke was significant between groups (p = 0.01),
and post-hoc comparison showed a significantly larger number of smokers in the any ED
group (15.0%) in comparison to the other groups. The number of cigarettes/day was signifi-
cantly different across groups (p = 0.004), in that it was larger in the sexually inactive group
(17.1 ± 8.5) than in the any ED group (13.9 ± 8.6; Table 3).
The use of psychoactive drugs significantly differed across groups (p< 0.001), and post-hoc
showed that it was smaller in the no ED group (30.4%) in comparison to the other ones. The
type of psychoactive drugs also differed across groups (p = 0.001), in that post-hoc showed sig-
nificant difference between the no ED group and the other ones. Among psychoactive drugs,
the use of benzodiazepines (p = 0.001), neuroleptics (p = 0.034), and more than a single active
principle (p = 0.019) significantly differed between groups (Table 3). Daily OMMED was sig-
nificant between groups (p = 0.032), and post-hoc showed that it was smaller in the no ED
group (270.1 ± 237.5) than in the sexually inactive one (310.2 ± 229.0; Table 3).
Table 2. Clinical characteristics of the patients.
Variable
Smoke† 86 (10.8%), 711 (89.2%)
Cigarettes/day mean: 15.2 ± 9.1, median: 15, range: 0–70
Psychoactive drugs‡ 502 (63.0%), 295 (37.0%)
Antidepressants 57 (7.2%)
Benzodiazepines 148 (18.6%)
Neuroleptics 20 (2.5%)
More than one 70 (8.8%)
Opioid agonist§ 598 (75.0%), 199 (25.0%)
Daily OMMED (mg) mean: 282.7 ± 229.7, median: 235, range: 9.4–1645
SCL-90-R GSI mean: 0.8 ± 0.6, median: 0.6, range: 0–3.6
GHQ-12 score mean: 13.6 ± 6.4, median: 12, range: 0–36
†Smoke: no, yes (%).
‡Psychoactive drugs: no, yes (%).
§Opioid agonist: methadone, buprenorphine (%). OMMED: oral morphine milligram equivalent dosage. SCL-
90-R GSI: Symptom Check List-90-R global severity index. GHQ-12: 12-Items General Health
Questionnaire.
https://doi.org/10.1371/journal.pone.0188994.t002
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GHQ-12 score significantly differed across groups (p< 0.001), in that it was smaller (i.e.,
better QoL) in the no ED group than the other ones.
The other demographical and clinical variables were not significant between groups
(Table 3).
SCL-90-R GSI was significantly different across groups (p< 0.001), and all post-hoc com-
parisons were significant (Fig 1). All SCL-90-R subscales, except HOS (n.s.) were significantly
different (SOM: p = 0.005, OC: p< 0.001, IS: p< 0.001, DEP: p< 0.001, ANX: p< 0.001,
PHO: p< 0.001, PAR: p = 0.013, PSY: p< 0.001). Post-hoc showed significant difference in
sexually inactive vs. no ED groups comparison for all subscales except HOS, in any ED vs. no
ED groups comparison for OC, IS, DEP, ANX, PHO and PSY subscales, and in sexually inac-
tive vs. any ED groups comparison for IS and DEP (Fig 1).
Age (ρ = -0.18, p< 0.001) and daily OMMED (ρ = -0.08, p = 0.025) were significantly and
negatively correlated with the IIEF-5 score, while no significant correlation was found between
the number of cigarettes/day and IIEF-5 score. A significant negative correlation was found
between IIEF-5 score and GHQ-12 score (ρ = -0.18, p< 0.001).
For sexually active patients (N = 701), covariates, which turned out significant in previous
between-groups analyses (i.e., age, employment, smoke, cigarettes/day, psychoactive drug, psy-
choactive drug type, daily OMMED, all SCL-90-R subscales except HOS) were entered into
multivariate analysis. Multivariate logistic regression model showed that psychoactive drugs
Table 3. Demographic and clinical characteristics of the patients according to the presence of erectile dysfunction (ED).
Variable Sexually inactive (N = 96) Any ED (N = 293) No ED (N = 408) P
Demographic
Age (y) 42.9 ± 11.3* 39.4 ± 9.5* 37.2 ± 9.5* <0.001
Education† 65 (67.7%), 30 (31.3%), 1 (1.0%) 179 (61.1%), 105 (35.8%), 9 (3.1%) 249 (61.0%), 148 (36.3%), 11 (2.7%) n.s.
Employment‡ 53 (55.2%), 43 (44.8%)* 142 (48.5%), 151 (51.5%) 171 (41.9%), 237 (58.1%)* 0.034
Marital status§ 84 (87.5%), 12 (12.5%) 245 (83.6%), 48 (16.4%) 340 (83.3%), 68 (16.7%) n.s.
Parenthood¶ 77 (80.2%), 19 (19.8%) 257 (87.7%), 36 (12.3%) 347 (85.0%), 61 (15.0%) n.s.
Clinical
Smoke¶ 6 (6.3%), 90 (93.7%) 44 (15.0%), 249 (85.0%)** 36 (8.8%), 372 (91.2%) 0.01
Cigarettes/day 17.1 ± 8.5* 13.9 ± 8.6* 15.6 ± 9.6 0.004
Psychoactive drugs¶ 53 (55.2%), 43 (44.8%) 165 (56.3%), 128 (43.7%) 284 (69.6%), 124 (30.4%)*** <0.001
Psychoactive drug typeß 0.001***
Antidepressants 9 (9.4%) 25 (8.5%) 23 (5.6%) n.s.
Benzodiazepines 17 (17.7%) 68 (23.2%)* 63 (15.4%)* 0.007
Neuroleptics 2 (2.1%) 12 (4.1%)* 6 (1.5%)* 0.034
More than one 15 (15.6%)* 24 (8.2%) 31 (7.6%)* 0.019
Opioid agonist# 77 (80.2%), 19 (19.8%) 219 (74.7%), 74 (25.3%) 302 (74.0%), 106 (26.0%) n.s.
Daily OMMED (mg) 310.2 ± 229.0* 291.3 ± 218.2 270.1 ± 237.5* 0.032
GHQ-12 score 15.3 ± 6.7 14.3 ± 6.5 12.7 ± 6.0** <0.001
†Education: grade school, high school, university.
‡Employment: unemployed, employed.
§Marital status: single/divorced, engaged/married. ¶Parenthood, smoke, psychoactive drugs: no, yes. ßPsychoactive drug type: number of patients (%).
#Opioid agonist: methadone, buprenorphine (%).
*Significant difference between groups to post-hoc comparison.
**Significant difference vs. the other two groups to post-hoc comparison.
***No ED group significantly different from the other two groups to post-hoc comparison. OMMED: oral morphine milligram equivalent dosage.
GHQ-12: 12-Items General Health Questionnaire.
https://doi.org/10.1371/journal.pone.0188994.t003
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and some SCL-90-R subscales (i.e., DEP, ANX, PHO, PSY) had significant direct effect, and
the number of cigarettes/day had significant inverse effect on the risk of developing any ED,
while the other covariates were not significant (Table 4). Linear regression model showed that
employment, smoke, and some SCL-90-R subscales (i.e., DEP, ANX, PAR, PSY) had signifi-
cant positive effect, while age, psychoactive drugs, and daily OMMED had significant negative
effect on IIEF-5 score (Table 5).
Multivariate linear regression model was applied to explore the influence of demographic
(age, education, marital status, parenthood), clinical variables (type of opioid, daily OMMED,
smoke, cigarettes, psychoactive drugs, type of psychoactive drug), SCL-90-R GSI, and IIEF-5
score on GHQ-12 scores in sexually active patients (N = 701). Age, education, daily OMMED,
IIEF-5 score, and SCL-90-R GSI significantly worsened, while employment significantly ame-
liorated QoL according to GHQ-12 score (Table 6).
Fig 1. Psychopathological symptoms according to the Symptom Check List-90-R. SCL-90-R:
Symptom Check List-90-R. GSI: global severity index. SOM: somatization. OC: obsessive-compulsive. IS:
interpersonal sensitivity. DEP: depression. ANX: anxiety. HOS: hostility. PHO: phobic anxiety. PAR: paranoid
ideation. PSY: psychoticism (PSY). ED: erectile dysfunction. *Significant sexually inactive vs. no ED groups
post-hoc comparison (p < 0.016). **No ED group significantly different from the two other groups to post-hoc
comparison (p < 0.016). ***All post-hoc comparisons were significant (p < 0.016).
https://doi.org/10.1371/journal.pone.0188994.g001
Table 4. Logistic regression model analysis for the risk of developing any erectile dysfunction (ED).
Significant covariates OR 95% CI P value
Cigarettes/day 0.97 0.96; 0.99 0.002
Psychoactive drugs† 1.62 1.17; 2.24 0.003
SCL-90-R subscales
DEP 2.25 1.43; 3.53 <0.001
ANX 2.30 1.59; 3.35 0.005
PHO 1.89 1.13; 3.12 0.015
PSY 1.70 1.02; 2.82 0.041
Here are reported only covariates that turned out to be significant in multivariate logistic regression analysis.
OR: odds ratio. CI: confidence interval.
†Psychoactive drugs: 0 = no, 1 = yes. SCL-90-R: Symptom Check List-90-R. DEP: depression. ANX:
anxiety. PHO: phobic anxiety. PSY: psychoticism.
https://doi.org/10.1371/journal.pone.0188994.t004
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Discussion
To the best of our knowledge, this is the largest report on ED in men on methadone or bupre-
norphine maintenance treatment. The main findings, which will be discussed below, were as
follows: a) nearly half of patients in our sample were sexually inactive or reported some degree
of ED; b) some demographic and clinical variables, as well as most of psychopathological
symptoms measured with the SCL-90-R, significantly differed according to the presence or
absence of ED; c) multivariate regression model indicated that age, employment, smoke, psy-
choactive drugs, daily OMMED and some SCL-90-R subscales significantly influenced the risk
and severity of ED; d) QoL was worse in patients with ED and significantly correlated with ED
severity; e) age, education, employment, daily OMMED, IIEF-5 score, and SCL-90-R GSI sig-
nificantly influenced QoL in the multivariate analysis.
Table 5. Linear regression model analysis for the IIEF-5 score.
Significant covariates β 95% CI P value
Age (y) -0.23 -0.20; -0.27 <0.001
Employment† 3.84 2.87; 4.81 <0.001
Smoke‡ 7.87 6.58; 9.17 <0.001
Psychoactive drugs¶ -2.03 -4.13; -0.36 0.035
Daily OMMED (mg) -0.03 -0.01; -0.05 0.003
SCL-90-R subscales
DEP -1.79 -3.18; -0.30 0.019
ANX -2.11 -3.79; -0.44 0.014
PAR -2.03 -3.12; -0.94 <0.001
PSY -2.60 -4.15; -1.04 0.001
Here are reported only covariates that turned out to be significant in multivariate linear regression analysis.
Please note that higher IIEF-5 scores indicated better erectile dysfunction.
†Employment: 0 = unemployed, 1 = employed.
‡Smoke: 0 = no, 1 = yes.
¶Psychoactive drugs: 0 = no, 1 = yes. IIEF-5: International Index of Erectile Function. CI: confidence interval.
OMMED: oral morphine milligram equivalent dosage. SCL-90-R: Symptom Check List-90-R. DEP:
depression. ANX: anxiety. PAR: paranoid ideation. PSY: psychoticism.
https://doi.org/10.1371/journal.pone.0188994.t005
Table 6. Linear regression model analysis for the GHQ-12 score.
Significant covariates β 95% CI P value
Age (y) 0.13 0.10; 0.16 0.014
Education† 0.73 0.12; 1.33 0.02
Employment‡ -1.02 -1.76; -0.28 0.007
Daily OMMED (mg) 0.02 0.00; 0.03 0.042
IIEF-5 score -0.83 -1.34; -0.31 0.002
SCL-90-R GSI 7.47 6.85; 8.08 <0.001
Here are reported only covariates that turned out to be significant in multivariate linear regression analysis.
Please note that higher GHQ-12 score indicates worse quality of life.
†Education: 0 = grade school, 1 = high school, 2 = university.
‡Employment: 0 = unemployed, 1 = employed. GHQ-12: 12-Items General Health Questionnaire. CI:
confidence interval. OMMED: oral morphine milligram equivalent dosage. IIEF-5: International Index of
Erectile Function. SCL-90-R: Symptom Check List-90-R. GSI: global severity index.
https://doi.org/10.1371/journal.pone.0188994.t006
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The 36.8% prevalence of any ED in our sample is in line with previous studies [7,9,11].
Among our patients, 12% were sexually inactive, but we have no information whether this was
caused by the severity of ED, or by other factors.
Despite the severity of ED was reported to range from mild to moderate in many patients,
its impact was relevant, given the relatively young age of our sample (mean age: 38.6 years).
Moreover, the possibility that some patients reported less severe ED symptoms because they
felt uncomfortable or embarrassed should be considered [29].
Age was significantly higher in patients with ED and significantly correlated with ED sever-
ity (i.e., the higher the age, the more severe the ED) in multivariate analysis. This finding is in
keeping with those in opioid users [9,10,13,30], and in the general population [2, 4].
Being employed was found to be associated with reduced severity of ED in our study. This
factor was either not consistently associated with ED, or seldom explored in previous studies.
Since a direct cause-effect relationship between employment and sexual dysfunction is difficult
to hypothesize, we may speculate that psychological and social consequences of being
employed might have reduced the severity of ED in our patients.
At variance from previous reports [6,7], marital status did not turn out to be associated
with ED in the present study. Differences between the samples or cross-cultural differences [6]
might have contributed to this finding.
The effect of smoke appears to be complex in our group of patients. Smoking was more fre-
quent in patients with ED, and was a significant predictor of ED severity in multivariate analysis
(i.e., more severe ED in smokers). The number of daily cigarettes turned out to be significantly
higher in sexually inactive patients than those with ED, and a significant predictor of any ED in
logistic multivariate analysis (i.e., the smaller the number of cigarettes/day, the higher the risk of
ED). While smoke stands amongst the main factors associated with ED in general population
[2,4], the role of this factor was unclear in previous studies on men using opioids [10,13,30].
Smoke, which is common in people using opioids [31], may contribute to ED through increase in
oxidative stress and inflammatory markers, that bring about vascular changes [32]. Having been
the assessment of this factor based on self-report in our study, a recall (i.e., patients did not pre-
cisely remember the number of daily cigarettes) or response bias (i.e., patients reported a smaller
number of daily cigarettes) might have contributed to the apparently contrasting finding that the
number of cigarettes/day was inversely associated with the risk of ED. Moreover, smokers often
vary their smoking habits over the years, and the use of smoking pack-years instead of daily ciga-
rettes would have represented a better measure of lifetime tobacco exposure in our patients.
The use of other psychoactive drug was less common in patients with no ED than those
with any ED or who were sexually inactive, and this factor was significant predictor for the risk
of any ED and its severity. Benzodiazepines and neuroleptics were found to be more frequent
in patients with ED than those with no ED, and the use of more than one class of psychoactive
drugs was more frequent in sexually inactive patients than those with no ED. This finding,
which is in accordance with previous studies [13,33], is not surprising, since psychoactive
drugs may have negative effects on sexual function through various mechanisms. Moreover,
the coexisting psychopathology might contribute to ED through psychological mechanisms.
Of interest, antidepressants, which were reported to be associated with sexual dysfunction in
previous reports [30,34], did not differ across groups in our sample.
We did not find significant difference between methadone and buprenorphine treatment.
Previous studies reported contrasting results on this point [7–9,19,20], with a meta-analysis
indicating that methadone has 4.01 odds ratio (95% CI: 1.52–10.55) for sexual dysfunction in
comparison to buprenorphine [13]. Reasons for previous contrasting data might include the
small number of patients, and/or the absence of multivariate analysis to correct for potential
confounders.
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Daily OMMED significantly differed between groups, being larger in sexually inactive patients,
intermediate in patients who reported any ED, and smaller in those with no ED. Moreover, daily
OMMED was significantly correlated with the IIEF-5 score (i.e., the larger the dosage, the more
severe the ED), and the correlation survived multivariate analysis. Data from previous studies are
conflicting on this point, as some of them found significant correlation between opioid dosage
and sexual dysfunction [35,36], while other ones reported negative findings [6,7]. It is tempting to
speculate that higher opioid dosage could have resulted in more marked effects on hypothalamic–
pituitary axis that in turn might have been responsible for ED in our patients.
Nearly all SCL-90-R subscales were significantly different across groups, being more severe
in sexually inactive patients than any ED and no ED groups. For some subscales, a significant
difference was found when comparing patients with ED to those without ED. Five SCL-90-R
subscales (i.e., DEP, ANX, PHO, PAR, PSY) were significant predictor of either the risk of ED
or its severity in multivariate analysis. These data, which are in accordance with previous stud-
ies in the general population with no medical problems [5], and in patients receiving opioid
maintenance treatment [7,37], underscore the importance of comorbid psychopathology in
patients with ED. The association might be bidirectional, because psychological factors may
result in ED that, in turn, may worsen psychopathology [7]. Future longitudinal studies would
be important to better explore the directionality of the cause-effect relationship between psy-
chological comorbidity and ED.
Despite the recommendation that androgen replacement therapy should be considered in
males diagnosed with OPIAD [17], none of our patients were on this treatment. A small
minority of them (i.e., 6.4% of sexually active patients with any ED) received treatment for ED.
These figures appear to differ from those in patients under long-term opioids for back pain,
19% of whom were reported to receive prescription for ED or androgen replacement therapy,
especially in case of high dosage and longer duration of opioid treatment [38]. Reasons for this
negative finding in our sample might include concern on the possible cardiovascular and
hepatic side effects, the risk of prostate cancer, or the lack of awareness for this therapy by the
treating physicians and/or patients.
QoL was significantly worse in patients who were sexually inactive or who reported ED in
comparison to those with no ED. A significant correlation was found between IIEF-5 and
GHQ-12 scores, and multivariate analysis showed that ED score was a predictor of QoL
impairment (i.e., the worse the ED, the worse the QoL). The other factors that influenced QoL
severity were age, education, employment, daily OMMED, and SCL-90-R GSI, most of which
were found to significantly influence ED. It is not surprising that ED may impact on QoL
through impairment of physical and psychological functioning, but surprisingly this outcome
was seldom explored in men under ORT [6,8,21,22].
The first and most important limitation of the present study is the lack of data on testoster-
one or hypogonadism, but previous studies reported no correlation between testosterone levels
and ED severity, especially in younger men, probably because serum levels do not reflect bio-
logically available testosterone, a more accurate marker of hypogonadism [9,30]. The second
limitation is that, because of the large sample in the present study, the assessment of ED was
subjective and patients did not undergo objective measures, which could have helped better
separate physical and psychological determinants of ED. The third limitation is possible
response bias, since some patients might have concealed or reported a smaller severity of their
symptoms, because they felt uncomfortable or embarrassed when answering questions on ED
[8]. This hypothesis is strengthened by the relatively large number of patients (nearly 20%),
who preferred not to answer the IIEF-5 questionnaire and were not included in the study.
Other limitations include the cross-sectional nature of the study, and the lack of information
on coexisting viral infections, such as viral hepatitis or HIV. Hepatitis C virus infection, a
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common comorbid condition in opioid users, can negatively affect sex hormone levels, but its
role in ED is still contradictory [39,40].
Our data showed that nearly half of our patients under ORT reported ED or were sexually
inactive, ED severity was significantly correlated to QoL, and cigarette smoking and use of psy-
chotropic drugs was predictive of ED. Sexuality is still a neglected issue in people with sub-
stance use disorders, but sexual and ED may have important effects on emotional and social
well-being, including self-esteem and sense of self-efficacy, and may affect outcome by improv-
ing adherence to treatment [8]. Exploring ED complaints in men using opioids under ORT is
a critical component of care, because self-report on this problem still occurs in a minority of
patients [41], and IIEF-5 represents a simple and quick self-assessment tool. Counselling
patients about the importance of smoking cessation is paramount especially in this population.
Future studies should explore whether reducing ED symptoms in men under ORT might
improve QoL, and reduce relapse into opioid use.
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